NCT03560973 · CITED IN SOURCE DOCUMENTS

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2025-03-13

Study RAMES is a multicentre, double-blind, randomized Phase II study exploring the efficacy and evaluating the safety of the addition of ramucirumab to gemcitabine as the second-line treatment of patients with diffuse pleural mesothelioma. Patients will be randomly assigned (1:1) to receive intravenous gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days with placebo or combined with intravenous ramucirumab 10 mg/Kg (ramucirumab group) on day 1 of a 21 day cycle until PD. Randomisation will be done via a centralized system and will stratified by performance status (0-1 vs 2), age (≤70 vs \>70), histology (epithelioid vs others), time to progression (TTP) after a previous treatment (first line therapy, adjuvant or neoadjuvant therapy) (\< 6 months vs ≥6 months).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: Inclusion Criteria: 1. The patient has a histopathologically or cytologically confirmed diagnosis of malignant pleural mesothelioma. 2. The patient has documented disease progression after the last dose of first-line chemotherapy for metastatic disease, a. Patients who are intolerant to first-line chemotherapy regimens are eligible. Disease progression must be assessed after the last dose of first-line therapy. 3. The patient received combination chemotherapy prior to disease progression. 1. Prior chemotherapy regimens must include a platinum or pemetrexed component. Exposure to antineoplastic therapy, in addition to platinum and/or pemetrexed, is acceptable if the agents were used in the first-line metastatic or neoadjuvant/adjuvant setting. 2. Patients who have had one or more components of first-line chemotherapy discontinued because of toxicity, but continued to receive the other component(s), are eligible following disease progression. 4. The patient has metastatic disease or locally advanced disease that is measurable, or nonmeasurable but evaluable, by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) (Eisenhauer et al. 2009 Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using intravenous and oral contrast unless clinically contraindicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed. 5. The patient has an ECOG performance status of 0-2 6. The patient has adequate organ function. 7. The patient is at least 18 years old or of an acceptable age according to local regulations, whichever is older. 8. The patient has provided written informed consent prior to any study-specific procedures and is amenable to compliance with protocol schedules and testing. 9. The patient has an estimated life expectancy of 12 weeks in the judgment of the investigator. 10. The patient has resolution to Grade 1 by Common Terminology Criteria for Adverse Events CTCAE Version 4 NCI 2009, of all clinically significant toxic effects of previous anticancer therapy. 11. The patient, if male, is sterile (including vasectomy confirmed by post-vasectomy semen analysis) or agrees to use a reliable method of birth control and to not donate sperm during the study and for at least 12 weeks following the last dose of study treatment. 12. The patient, if female, is surgically sterile, is postmenopausal, or agrees to use a highly effective method of birth control during the study and for 12 weeks following the last dose of study treatment. A highly effective method of birth control is defined as one that results in a low failure rate when used consistently and correctly. 13. The patient, if female and of child-bearing potential, must have a negative serum or urine pregnancy test within 7 days prior to randomization. Exclusion Criteria: 14. The patient has cancer with histology other than mesothelioma. 15. The patient is receiving chronic therapy with any of the following within 7 days prior to randomization: 1. nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents) 2. other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide) Aspirin use at doses up to 325 mg/day is permitted. 16. The patient received radiotherapy within 14 days prior to randomization. Any lesion requiring palliative radiotherapy or which has been previously irradiated cannot be considered for response assessment. 17. The patient received \>1 line of prior therapy for the treatment MPM. 18. The patient received previous treatment with agents targeting the VEGF/VEGF Receptor 2 signaling pathway, including previous exposure to ramucirumab. 19. The patient has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression. Screening of asymptomatic patients is not required. 20. The patient has a significant bleeding disorder or vasculitis or had a Grade 3 bleeding episode within 12 weeks prior to randomization. 21. The patient experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization. 22. The patient has symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia. 23. The patient has uncontrolled hypertension, as defined in CTCAE Version 4.0, prior to initiating study treatment, despite antihypertensive intervention. CTCAE Version 4.0 defines uncontrolled hypertension as Grade \>2 hypertension; clinically, the patient continues to experience elevated blood pressure (systolic \>160 mmHg and/or diastolic \>100 mmHg) despite medications). 24. The patient underwent major surgery within 28 days prior to randomization or central venous access device placement within 7 days prior to randomization. The patient has a serious or nonhealing wound, ulcer or bone fracture within 28 days prior to enrollment. 25. The patient has selective or planned major surgery to be performed during the course of clinical trial. 26. The patient has a history of gastrointestinal (GI) perforation or fistula within 6 months prior to randomization. 27. The patient has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) 12 months prior to randomization. 28. The patient has an acute or subacute bowel obstruction or history of chronic diarrhoea that is considered clinically significant in the opinion of the investigator. 29. The patient has either of the following: 1. cirrhosis at a level of Child-Pugh B (or worse) 2. cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis. 30. The patient has known allergy or hypersensitivity to any components of study treatment. 31. The patient received any previous investigational therapy within 4 half -lives of the investigational agent prior to randomization. 32. The patient has a serious illness or medical condition including, but not limited to, the following: 1. known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness 2. active or uncontrolled clinically serious infection 33. The patient is pregnant or breast-feeding. 34. The patient has a concurrent active malignancy other than the following: 1. adequately treated not melanomatous skin cancer 2. curatively treated in situ carcinoma of the cervix or other not invasive carcinoma or in situ neoplasm A patient with a history of prior malignancy is eligible if he or she has been disease free for 3 years prior to randomization. 35. The patient has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone fracture, within 28 days prior to randomization. 36. The patient experienced any Grade 3 or 4 venous thromboembolic event (VTE) that is considered by the investigator to be life-threatening or that is symptomatic and not adequately treated by anticoagulation therapy, within 6 months prior to randomization (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") 37. The patient has any condition (for example, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggests that the patient is, in the investigator's opinion, not an appropriate candidate for the study.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
intervention Names
Drug: Gemcitabine
Drug: Ramucirumab
label
Gemcitabine + Ramucirumab
type
EXPERIMENTAL
description
Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
intervention Names
Drug: Gemcitabine
label
Gemcitabine + Placebo
type
PLACEBO_COMPARATOR

interventions

arm Group Labels
Gemcitabine + Placebo
Gemcitabine + Ramucirumab
description
ramucirumab/ placebo was added to gemcitabine
name
Gemcitabine
other Names
gemsol
type
DRUG
arm Group Labels
Gemcitabine + Ramucirumab
description
ramucirumab/ placebo was added to gemcitabine
name
Ramucirumab
other Names
CYRAMZA
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: QUADRUPLE
who Masked: PARTICIPANT
CARE_PROVIDER
INVESTIGATOR
OUTCOMES_ASSESSOR

primary Purpose

TREATMENT

Enrollment

count: 164
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
time from the date of randomization to the date of death from any cause. gemcitabine with placebo,
measure
OS
time Frame
36 months

secondary Outcomes

description
Progression-free survival (PFS) is measured from the date of randomization to the date of radiographic documentation of progression (as defined by RECIST v1.1) or the date of death due to any cause, whichever is earlier. RECIST 1.1
measure
PFS
time Frame
36 months
description
TEAEs, AESIs, SAEs, and hospitalizations, Clinical laboratory tests, vital signs, and physical examinations
measure
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).
time Frame
36 months
description
ORR is the proportion of randomized patients achieving a best overall response of complete response (CR) or partial response (PR).
measure
ORR
time Frame
36 months
description
DCR is the proportion of randomized patients achieving a best overall response of CR, PR, or stable disease (SD).
measure
DCR
time Frame
36 months
description
polymorphisms associated with ramucirumab response
measure
Predictive molecular markers
time Frame
36 months
description
survey completed by patients at cycles
measure
Quality life
time Frame
36 months
description
Evaluation of circulating pro-angiogenic factors in response to Ramucirumab treatment
measure
Predictive molecular markers
time Frame
36 months
description
Effect of the mutational asset of the tumor on Ramucirumab response
measure
Predictive molecular markers
time Frame
36 months

Full study description

brief Summary: Study RAMES is a multicentre, double-blind, randomized Phase II study exploring the efficacy and evaluating the safety of the addition of ramucirumab to gemcitabine as the second-line treatment of patients with diffuse pleural mesothelioma. Patients will be randomly assigned (1:1) to receive intravenous gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days with placebo or combined with intravenous ramucirumab 10 mg/Kg (ramucirumab group) on day 1 of a 21 day cycle until PD. Randomisation will be done via a centralized system and will stratified by performance status (0-1 vs 2), age (≤70 vs \>70), histology (epithelioid vs others), time to progression (TTP) after a previous treatment (first line therapy, adjuvant or neoadjuvant therapy) (\< 6 months vs ≥6 months).

Source references

references

citation
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6.
pmid
34499874
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-bd209c205de612b94e35
requested nct id
NCT03560973
primary nct id
NCT03560973
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq
source record id
Source null
source file sha256
1414c84a4d62873b5e1f4c2832430369c228f1c8a2fd419cc0023c23c4547bb7
payload sha256
afb0ffb4a0f49b32f41a0b917ddc711471ad944da8538eab2cbeddb19347859e
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-bd209c205de612b94e35
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT03560973
occurrences
context exact
<div class="pdq-content-list"><ol id="_313"><li>A multicenter, randomized, double-blind, placebo-controlled, phase II trial (<a href="/clinicaltrials/NCT03560973">RAMES</a> [NCT03560973]) included 161 patients with malignant pleural mesothelioma that progressed during or after first-line treatment with pemetrexed plus p
end
100567
exact text
NCT03560973
start
100556
context exact
q-content-list"><ol id="_313"><li>A multicenter, randomized, double-blind, placebo-controlled, phase II trial (<a href="/clinicaltrials/NCT03560973">RAMES</a> [NCT03560973]) included 161 patients with malignant pleural mesothelioma that progressed during or after first-line treatment with pemetrexed plus platinum. Patients were r
end
100591
exact text
NCT03560973
start
100580
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/d2ad6f5dbc37304e2d.html
source file sha256
1414c84a4d62873b5e1f4c2832430369c228f1c8a2fd419cc0023c23c4547bb7
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:22:06.513704+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
28e496963d85371366c38534c5a66390d33a7c2e63d0260c22acbc39e0c011a9
source title
Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: May 12, 2025
datetime
2025-05-12T12:00:00Z
display
May 12, 2025
source url
https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq

Preserved source evidence · Not medical advice